Natera

Natera is a global leader in cell-free DNA (cfDNA) testing, committed to transforming healthcare management through advanced genetic diagnostics. Founded with a personal mission to improve the lives of families affected by genetic diseases, Natera specializes in oncology, women’s health, and organ health. Their innovative products include the Signatera test for assessing residual cancer disease, Prospera tests for transplant assessments, and a suite of women’s health screenings such as Panorama for noninvasive prenatal testing.

Natera’s services are designed for both patients and clinicians, offering detailed, clear reports and expert support to ensure that test results are easily understood. Their commitment to research is evident, with extensive clinical validation and participation in leading studies like SMART and CIRCULATE. As a CLIA-certified and CAP-accredited laboratory, Natera adheres to stringent quality standards, advocating for personalized medicine to foster earlier interventions, ultimately leading to longer, healthier lives. With a focus on innovation, integrity, and sustainability, Natera is at the forefront of molecular diagnostics, making a significant impact on healthcare worldwide.